Q1 Net Loss Widens to $12.8M; Raises $25.9M via ATM Offering Amidst Upcoming FDA Decision

summarizeSummary

Unicycive Therapeutics reported a widened net loss in Q1 2026 but secured $25.9 million through dilutive ATM offerings, providing essential liquidity ahead of a critical FDA decision for its OLC drug candidate.

check_boxKey Events

• Increased Net Loss

  The company reported a net loss of $12.8 million for Q1 2026, a significant increase from a net income of $0.6 million in Q1 2025.

• Substantial Capital Raise via ATM Offering

  Unicycive raised $19.6 million in net proceeds during Q1 2026 by selling 3,123,537 shares at an average price of $6.46. An additional $6.3 million was raised post-quarter end by selling 1,000,000 shares at an average price of $6.45. This represents a total of $25.9 million in new capital, which is highly dilutive but extends the company's cash runway.

• Critical FDA Decision Approaching

  The PDUFA target action date for the OLC NDA resubmission is set for June 29, 2026, following FDA acceptance of the resubmission in January 2026.

• Ongoing Legal Challenges

  The company faces ongoing shareholder class action and derivative lawsuits related to alleged misrepresentations regarding OLC manufacturing and approval prospects, with recent updates on motions to dismiss and consolidation of actions.

auto_awesomeAnalysis

Unicycive Therapeutics reported a significant increase in its net loss for Q1 2026, reaching $12.8 million compared to a net income of $0.6 million in Q1 2025. To bolster its financial position, the company raised a substantial $19.6 million in net proceeds from an At-The-Market (ATM) offering during Q1 2026, selling 3.1 million shares at an average price of $6.46. An additional $6.3 million was raised post-quarter end by selling 1 million shares at $6.45. This capital raise, totaling $25.9 million, is highly dilutive, representing approximately 13% of the company's market capitalization, but provides crucial liquidity for a clinical-stage biotech. The company maintains a cash runway of at least one year. Investors are closely watching the upcoming PDUFA date of June 29, 2026, for the OLC NDA resubmission, which remains a critical near-term value driver. Ongoing shareholder lawsuits related to OLC manufacturing and approval prospects continue to be a significant legal overhang.